{
    "root": "e8f6d534-115c-440e-bdbb-b443a29bb468",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Yutrepia",
    "value": "20250523",
    "ingredients": [
        {
            "name": "TREPROSTINIL SODIUM",
            "code": "7JZ75N2NT6",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50863"
        },
        {
            "name": "TREHALOSE DIHYDRATE",
            "code": "7YIN7J07X4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_232797"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53426"
        },
        {
            "name": "LEUCINE",
            "code": "GMW67QNF9C",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_25017"
        },
        {
            "name": "TRISODIUM CITRATE DIHYDRATE",
            "code": "B22547B95K"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26710"
        }
    ],
    "indications": {
        "text": "\u2022 pulmonary arterial hypertension ( pah ; group 1 ) improve exercise ability . establishing effectiveness predominately included patients nyha functional class iii symptoms etiologies idiopathic heritable pah ( 56 % ) pah associated connective tissue diseases ( 33 % ) . ( 1.1 ) \u2022 pulmonary hypertension associated interstitial lung disease ( ph-ild ; group 3 ) improve exercise ability . study establishing effectiveness predominately included patients etiologies idiopathic interstitial pneumonia ( iip ) ( 45 % ) inclusive idiopathic pulmonary fibrosis ( ipf ) , combined pulmonary fibrosis emphysema ( cpfe ) ( 25 % ) , group 3 connective tissue disease ( 22 % ) . ( 1.2 )",
        "doid_entities": [
            {
                "text": "hypertension (DOID:10763)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10763"
            },
            {
                "text": "pulmonary hypertension (DOID:6432)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6432"
            },
            {
                "text": "interstitial lung disease (DOID:3082)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3082"
            },
            {
                "text": "lung disease (DOID:850)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_850"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "idiopathic interstitial pneumonia (DOID:2797)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2797"
            },
            {
                "text": "pneumonia (DOID:552)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_552"
            },
            {
                "text": "idiopathic pulmonary fibrosis (DOID:0050156)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050156"
            },
            {
                "text": "pulmonary fibrosis (DOID:3770)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3770"
            },
            {
                "text": "connective tissue disease (DOID:65)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_65"
            },
            {
                "text": "tissue disease (DOID:872)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_872"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 oral inhalation . swallow yutrepia capsules . provided inhaler ( 2 ) \u2022 yutrepia administered 3 5 times per day . contents capsule inhaled 2 breaths . ( 2.1 ) \u2022 full instructions dosing patients treprostinil-na\u00efve transitioning treprostinil inhalation solution yutrepia ( 2.1 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "yutrepia supplied carton consisting 1 capsule based , dry powder inhaler ( referred \u201c inhaler \u201d ) , 28 capsules ( 7 foil blister cards 4 capsules ) , 7 single-use cleaning brushes . individual capsule well connected air channel separate blister well containing desiccant strip . descriptions yutrepia carton capsule strength provided table 4 : table 4 : yutrepia carton contents capsule strength capsule strength ( mcg treprostinil ) capsule description ndc number 26.5 opaque yellow cap , clear body , imprinted \u201c liquidia 26.5 \u201d black ink radially cap 72964-011-01 53 opaque green cap , clear body , imprinted \u201c liquidia 53 \u201d white ink radially cap 72964-012-01 79.5 opaque blue cap , clear body , imprinted \u201c liquidia 79.5 \u201d white ink radially cap 72964-013-01 106 opaque purple cap , clear body , imprinted \u201c liquidia 106 \u201d white ink radially cap 72964-014-01 yutrepia inhalation powder capsules delivered using capsule-based inhaler . off-white plastic inhaler consists blue protective cap marked yutrepia base mouthpiece , capsule chamber , two blue push buttons . discard inhaler device 7 days 56 actuations , whichever comes first . store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . capsules remain blister protect moisture light , capsule removed ready administer dose . keep reach children .",
    "adverseReactions": "none",
    "indications_original": "\u2022 Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). ( 1.1 ) \u2022 Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. The study establishing effectiveness predominately included patients with etiologies of idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF), combined pulmonary fibrosis and emphysema (CPFE) (25%), and WHO Group 3 connective tissue disease (22%). ( 1.2 )",
    "contraindications_original": "\u2022 For oral inhalation only. Do not swallow YUTREPIA capsules. Use only with the provided inhaler ( 2 ) \u2022 YUTREPIA should be administered 3 to 5 times per day. The contents of each capsule can be inhaled in 2 breaths. ( 2.1 ) \u2022 See Dosage and Administration for full instructions on dosing of patients who are treprostinil-na\u00efve or transitioning from treprostinil inhalation solution to YUTREPIA ( 2.1 )",
    "warningsAndPrecautions_original": "YUTREPIA is supplied in a carton consisting of 1 capsule based, dry powder inhaler (referred to as \u201cinhaler\u201d), 28 capsules (7 foil blister cards of 4 capsules each), and 7 single-use cleaning brushes. The individual capsule well is connected by an air channel to a separate blister well containing a desiccant strip.  Descriptions of YUTREPIA carton by capsule strength are provided in Table 4 below:\n                  \n                     Table 4: YUTREPIA Carton Contents by Capsule Strength\n                     \n                     \n                     \n                     \n                        \n                           Capsule Strength(mcg treprostinil)\n                           Capsule Description\n                           NDC Number\n                        \n                     \n                     \n                        \n                           \n                              26.5\n                           \n                           \n                              Opaque yellow cap, clear body, imprinted with \u201cLIQUIDIA 26.5\u201d in black ink radially on cap\n                           \n                           \n                              72964-011-01\n                           \n                        \n                        \n                           \n                              53\n                           \n                           \n                              Opaque green cap, clear body, imprinted with \u201cLIQUIDIA 53\u201d in white ink radially on cap\n                           \n                           \n                              72964-012-01\n                           \n                        \n                        \n                           \n                              79.5\n                           \n                           \n                              Opaque blue cap, clear body, imprinted with \u201cLIQUIDIA 79.5\u201d in white ink radially on cap\n                           \n                           \n                              72964-013-01\n                           \n                        \n                        \n                           \n                              106\n                           \n                           \n                              Opaque purple cap, clear body, imprinted with \u201cLIQUIDIA 106\u201d in white ink radially on cap\n                           \n                           \n                              72964-014-01\n                           \n                        \n                     \n                  \n                  YUTREPIA inhalation powder capsules should only be delivered using the capsule-based inhaler. The off-white plastic inhaler consists of a blue protective cap marked with YUTREPIA and a base with a mouthpiece, capsule chamber, and two blue push buttons. Discard the inhaler device after 7 days of use or 56 actuations, whichever comes first.\n                  Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature].\n                  Capsules should remain in the blister to protect them from moisture and light, and each capsule should be removed only when ready to administer a dose.\n                  Keep out of the reach of children.",
    "adverseReactions_original": "None",
    "drug": [
        {
            "name": "Yutrepia",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50863"
        }
    ]
}